Zydus Gets USFDA Clearance for Verapamil ER Range

Zydus Lifesciences Limited has got the final approval of FDA on its Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg and 240 mg strengths.

This authorization authorizes the firm to sell a new generic copy of the medication in the US. Verapamil is a main drug used to treat high blood pressure and which also reduces the occurrence of severe cardiac and brain incidents including heart attacks and strokes.

The tablets are developed upon the Calan SR Extended Release formulation developed by USRLD which will be manufactured at the Zydus plant in Baddi, Himachal Pradesh.

Also Read: New Dynamics of Drug Distribution, Free Medicine Schemes in India

With hypertension being among the prevalent chronic diseases in the U.S., another extended-release verapamil product makes Zydus stable in a treatment-oriented market segment.

The 2025 data of IQVIA MAT of September shows that the U.S. sales of the Verapamil Hydrochloride Extended-Release Tablets were USD 24.5-million. This continuous demand of long-acting cardiovascular medications facilitates in enhancing the supply chain of common medications that have been commonly prescribed particularly those employed in controlling blood pressure.

This is a new clearance that adds to Zydus U.S. portfolio. Since starting its filing program in FY 2003 -04, the company now has 428 approvals and 487 ANDAs filed. This addition further strengthens Zydus in its provision of quality medicines to provide regulatory standards and consistent and persistent patient demand in the U.S. healthcare environment.